Delpazolid is under clinical development by LigaChem Biosciences and currently in Phase II for Mycobacterium Infections. According to GlobalData, Phase II drugs for Mycobacterium Infections have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Delpazolid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Delpazolid overview
Delpazolid (LCB-010371) is under development for the treatment of refractory Mycobacterium abscessus Complex Pulmonary disease (MABC), gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci infections, Streptococcus pneumoniae infections, multidrug-resistant tuberculosis infections and pulmonary tuberculosis. It is a next-generation oxazolidinone antibiotic administered through oral and intravenous route. It acts by targeting 23s ribosomal RNA.
LigaChem Biosciences overview
LigaChem Biosciences (LCB) is a biotechnology company that discovers and develops novel therapeutics for infectious diseases, oncology, and immuno-oncology indications. Its pipeline products include LCB14, LCB84, LCB71, LCB73, LCB97, LCB02A, LCB41A, LCB67, LCB69, LCB85, LCB20A, LCB42A, LCB19A, LCB91, LCB06A, LCB18A, LCB36A and others. The company products are used in the therapeutic areas of antibiotics, anti-fibrotics, oncology and antibody-drug conjugate (ADC) platform technology. It operates in China. LCB is headquartered in Daejeon, South Korea.
For a complete picture of Delpazolid’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
